Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.
Also called NCT02865850
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 369 participants
- Sponsor
- Registry
-
NCT02865850 -
2016-000838-21
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Germany, Italy, Mexico, Poland, Portugal, Russia, South Korea, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02865850. Randomized; no masking; primary purpose treatment. Start 2016-07 (actual); primary completion 2020-01-31 (actual). Results posted on 2022-07-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Condition
- Anemia
- Condition
- Dialysis-Dependent Chronic Kidney Disease
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct02865850- Content hash
75f1001ea6cc292d05fd4c99bfb574965554d517f2d7e885dd9d4ac1a0bedeff